nav-left cat-right
cat-right

BioFocus DPI Extends Drug Discovery Collaboration ...

BioFocus DPI has extended its drug discovery agreement with Eli Lilly and Company until end 2009. Under the terms of the agreement, BioFocus DPI will identify active compounds by screening of Lilly’s library compounds. The agreement extension announced today builds on the successful collaboration begun in March 2005. BioFocus DPI has been working with Lilly on discovering new compounds that target specific cellular...

IPR story 12- Patenting a mere idea

Jaidev had joined a leading Pharmaceutical Research Institute in India, for his Ph.D work. He reviewed his research plan thoroughly and also searched patents. Based on discussions with his guide, he formulated a very innovative research plan, pertaining to development of a new screening method for diabetic compounds. He started his work and after nearly 2 years of hard work, came up with very good data. He filed a patent...

BIO-Europe 2008: The World’s Leading Biotech...

CARLSBAD, Calif. & WASHINGTON — September 2, 2008 — The leaders of the biotechnology industry will once again gather for BIO-Europe, the world’s largest stand-alone partnering conference, in Mannheim/Heidelberg, Germany, November 17-19. With biotech deal-making still the thrill in drug development markets, this year’s BIO-Europe promises to set new standards for generating quality partnering...

FDA Issues Public Health Advisory on Chantix

The U.S. Food and Drug Administration (FDA) today issued a Public Health Advisory to alert health care providers, patients, and caregivers to new safety warnings concerning Chantix (varenicline), a prescription medication used to help patients stop smoking. On Nov. 20, 2007, FDA issued an Early Communication to the public and health care providers that the agency was evaluating postmarketing adverse event reports on Chantix...

Health Care’s Silent Spring

As the Intergovernmental Working Group (IGWG) of the WHO prepares to meet and discuss how to best facilitate the expropriation of intellectual property rights (in this case the IPR of pharmaceutical patents) it’s important to consider the unintended consequences — the death of medical innovation. The global purloiners of patents — led by Jamie Love — are thrilled to point out all of the new and...

BIO Spent $6.6 Million on Lobbying Efforts in 2007

The Biotech Industry Organization (“BIO”) spent $6.6 Million on lobbying efforts in 2007, reported the Associated Press. BIO’s lobbying efforts last year addressed a range of issues from patent reform to generics to FDA-related issues. The Associated Press reported as follows: [BIO’s] lobbying efforts went toward cloning issues ahead of the Food and Drug Administration’s ruling that cloned meat...
Page 3 of 41234